eXoZymes Inc Dossier
Qualitative Analysis
Business overview
eXoZymes Inc. (formerly Invizyne Technologies, Inc.) is a development-stage biotechnology company pioneering a cell-free biomanufacturing platform to produce high-value biochemicals, including active pharmaceutical ingredients (APIs), nutraceuticals, biofuels, and cosmetics. By utilizing artificial intelligence to design and optimize engineered enzymes (termed "exozymes") that operate in bioreactors outside of living cells, the company overcomes the toxicity, metabolic resistance, and purification bottlenecks that historically limit traditional cell-based synthetic biology. eXoZymes operates a capital-light business model focused on technology licensing, joint ventures, and spin-outs.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
The development and commercialization of NCT, a rare natural product that activates the cell's master metabolic control switch. The program targets metabolic wellness (over-the-counter) and pharmaceutical applications (metabolic diseases).
Expected impact: Establishes the first commercial-scale validation of the cell-free platform, opening up access to the multi-billion-dollar metabolic health and wellness markets.
An initiative designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions, focusing on group transfer reactions to support the automated design of novel small molecules.
Expected impact: Dramatically reduces the time and cost required to design and optimize exozyme pathways for novel drug development.
Development of cell-free technology to produce isobutanol from biomass for use as sustainable aviation fuel (SAF) and industrial chemicals.
Expected impact: Provides a high-potential entry into the rapidly growing sustainable aviation fuel market, which is projected to expand significantly due to global environmental mandates.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Cayman Chemical served as the independent partner that successfully validated and de-risked eXoZymes' cell-free biomanufacturing platform by executing a 100-liter pilot-scale run of NCT, proving process transferability and robustness under real-world conditions.
Terms: Specific financial terms of the partnership were not publicly disclosed.
Supported the advancement of eXoZymes' cell-free biomanufacturing platform toward commercial viability from 2023 to 2026 through technical guidance, separations evaluation, and technoeconomic and lifecycle analysis.
Terms: The program provided technical and advisory support; specific financial funding details under the accelerator were not fully disclosed.